Cargando…

MiR-21, miR-34a, miR-198 and miR-217 as diagnostic and prognostic biomarkers for chronic pancreatitis and pancreatic ductal adenocarcinoma

BACKGROUND: Pancreatic ductal adenocarcinoma is an aggressive malignancy with late presentation, metastatic potential and very poor prognosis. Therefore, there is an urgent need for novel diagnostic and prognostic biomarkers. MicroRNAs are small non-coding RNAs that post-transcriptionally regulate g...

Descripción completa

Detalles Bibliográficos
Autores principales: Vychytilova-Faltejskova, Petra, Kiss, Igor, Klusova, Sona, Hlavsa, Jan, Prochazka, Vladimir, Kala, Zdenek, Mazanec, Jan, Hausnerova, Jitka, Kren, Leos, Hermanova, Marketa, Lenz, Jiri, Karasek, Petr, Vyzula, Rostislav, Slaby, Ondrej
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4407796/
https://www.ncbi.nlm.nih.gov/pubmed/25908274
http://dx.doi.org/10.1186/s13000-015-0272-6
_version_ 1782367962360971264
author Vychytilova-Faltejskova, Petra
Kiss, Igor
Klusova, Sona
Hlavsa, Jan
Prochazka, Vladimir
Kala, Zdenek
Mazanec, Jan
Hausnerova, Jitka
Kren, Leos
Hermanova, Marketa
Lenz, Jiri
Karasek, Petr
Vyzula, Rostislav
Slaby, Ondrej
author_facet Vychytilova-Faltejskova, Petra
Kiss, Igor
Klusova, Sona
Hlavsa, Jan
Prochazka, Vladimir
Kala, Zdenek
Mazanec, Jan
Hausnerova, Jitka
Kren, Leos
Hermanova, Marketa
Lenz, Jiri
Karasek, Petr
Vyzula, Rostislav
Slaby, Ondrej
author_sort Vychytilova-Faltejskova, Petra
collection PubMed
description BACKGROUND: Pancreatic ductal adenocarcinoma is an aggressive malignancy with late presentation, metastatic potential and very poor prognosis. Therefore, there is an urgent need for novel diagnostic and prognostic biomarkers. MicroRNAs are small non-coding RNAs that post-transcriptionally regulate gene expression. Altered expression of microRNAs has been reported in wide range of malignancies, including pancreatic ductal adenocarcinoma. The aim of this study was to analyze the expression of selected microRNAs in normal pancreas, chronic pancreatitis and pancreatic ductal adenocarcinoma tissues and evaluate their diagnostic and prognostic potential. FINDINGS: Using quantitative real-time PCR, expression levels of 4 microRNAs were examined in 74 tumor tissues, 18 tissues of chronic pancreatitis and 9 adjacent normal tissues and correlated with clinicopathological features of patients. Expression levels of miR-21, miR-34a and miR-198 were significantly higher, whereas levels of miR-217 were significantly lower in pancreatic ductal adenocarcinomas compared to healthy tissues and tissues of chronic pancreatitis. Moreover, increased expression of miR-21 and miR-198 was significantly associated with shorter disease free survival and overall survival. CONCLUSIONS: Our data suggest that altered expression of examined microRNAs is related to neoplastic transformation and progression of the disease and these microRNAs could serve as diagnostic and prognostic biomarkers for pancreatic ductal adenocarcinoma. VIRTUAL SLIDES: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1373952531543898
format Online
Article
Text
id pubmed-4407796
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-44077962015-04-24 MiR-21, miR-34a, miR-198 and miR-217 as diagnostic and prognostic biomarkers for chronic pancreatitis and pancreatic ductal adenocarcinoma Vychytilova-Faltejskova, Petra Kiss, Igor Klusova, Sona Hlavsa, Jan Prochazka, Vladimir Kala, Zdenek Mazanec, Jan Hausnerova, Jitka Kren, Leos Hermanova, Marketa Lenz, Jiri Karasek, Petr Vyzula, Rostislav Slaby, Ondrej Diagn Pathol Short Report BACKGROUND: Pancreatic ductal adenocarcinoma is an aggressive malignancy with late presentation, metastatic potential and very poor prognosis. Therefore, there is an urgent need for novel diagnostic and prognostic biomarkers. MicroRNAs are small non-coding RNAs that post-transcriptionally regulate gene expression. Altered expression of microRNAs has been reported in wide range of malignancies, including pancreatic ductal adenocarcinoma. The aim of this study was to analyze the expression of selected microRNAs in normal pancreas, chronic pancreatitis and pancreatic ductal adenocarcinoma tissues and evaluate their diagnostic and prognostic potential. FINDINGS: Using quantitative real-time PCR, expression levels of 4 microRNAs were examined in 74 tumor tissues, 18 tissues of chronic pancreatitis and 9 adjacent normal tissues and correlated with clinicopathological features of patients. Expression levels of miR-21, miR-34a and miR-198 were significantly higher, whereas levels of miR-217 were significantly lower in pancreatic ductal adenocarcinomas compared to healthy tissues and tissues of chronic pancreatitis. Moreover, increased expression of miR-21 and miR-198 was significantly associated with shorter disease free survival and overall survival. CONCLUSIONS: Our data suggest that altered expression of examined microRNAs is related to neoplastic transformation and progression of the disease and these microRNAs could serve as diagnostic and prognostic biomarkers for pancreatic ductal adenocarcinoma. VIRTUAL SLIDES: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1373952531543898 BioMed Central 2015-04-24 /pmc/articles/PMC4407796/ /pubmed/25908274 http://dx.doi.org/10.1186/s13000-015-0272-6 Text en © Vychytilova-Faltejskova et al.; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Short Report
Vychytilova-Faltejskova, Petra
Kiss, Igor
Klusova, Sona
Hlavsa, Jan
Prochazka, Vladimir
Kala, Zdenek
Mazanec, Jan
Hausnerova, Jitka
Kren, Leos
Hermanova, Marketa
Lenz, Jiri
Karasek, Petr
Vyzula, Rostislav
Slaby, Ondrej
MiR-21, miR-34a, miR-198 and miR-217 as diagnostic and prognostic biomarkers for chronic pancreatitis and pancreatic ductal adenocarcinoma
title MiR-21, miR-34a, miR-198 and miR-217 as diagnostic and prognostic biomarkers for chronic pancreatitis and pancreatic ductal adenocarcinoma
title_full MiR-21, miR-34a, miR-198 and miR-217 as diagnostic and prognostic biomarkers for chronic pancreatitis and pancreatic ductal adenocarcinoma
title_fullStr MiR-21, miR-34a, miR-198 and miR-217 as diagnostic and prognostic biomarkers for chronic pancreatitis and pancreatic ductal adenocarcinoma
title_full_unstemmed MiR-21, miR-34a, miR-198 and miR-217 as diagnostic and prognostic biomarkers for chronic pancreatitis and pancreatic ductal adenocarcinoma
title_short MiR-21, miR-34a, miR-198 and miR-217 as diagnostic and prognostic biomarkers for chronic pancreatitis and pancreatic ductal adenocarcinoma
title_sort mir-21, mir-34a, mir-198 and mir-217 as diagnostic and prognostic biomarkers for chronic pancreatitis and pancreatic ductal adenocarcinoma
topic Short Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4407796/
https://www.ncbi.nlm.nih.gov/pubmed/25908274
http://dx.doi.org/10.1186/s13000-015-0272-6
work_keys_str_mv AT vychytilovafaltejskovapetra mir21mir34amir198andmir217asdiagnosticandprognosticbiomarkersforchronicpancreatitisandpancreaticductaladenocarcinoma
AT kissigor mir21mir34amir198andmir217asdiagnosticandprognosticbiomarkersforchronicpancreatitisandpancreaticductaladenocarcinoma
AT klusovasona mir21mir34amir198andmir217asdiagnosticandprognosticbiomarkersforchronicpancreatitisandpancreaticductaladenocarcinoma
AT hlavsajan mir21mir34amir198andmir217asdiagnosticandprognosticbiomarkersforchronicpancreatitisandpancreaticductaladenocarcinoma
AT prochazkavladimir mir21mir34amir198andmir217asdiagnosticandprognosticbiomarkersforchronicpancreatitisandpancreaticductaladenocarcinoma
AT kalazdenek mir21mir34amir198andmir217asdiagnosticandprognosticbiomarkersforchronicpancreatitisandpancreaticductaladenocarcinoma
AT mazanecjan mir21mir34amir198andmir217asdiagnosticandprognosticbiomarkersforchronicpancreatitisandpancreaticductaladenocarcinoma
AT hausnerovajitka mir21mir34amir198andmir217asdiagnosticandprognosticbiomarkersforchronicpancreatitisandpancreaticductaladenocarcinoma
AT krenleos mir21mir34amir198andmir217asdiagnosticandprognosticbiomarkersforchronicpancreatitisandpancreaticductaladenocarcinoma
AT hermanovamarketa mir21mir34amir198andmir217asdiagnosticandprognosticbiomarkersforchronicpancreatitisandpancreaticductaladenocarcinoma
AT lenzjiri mir21mir34amir198andmir217asdiagnosticandprognosticbiomarkersforchronicpancreatitisandpancreaticductaladenocarcinoma
AT karasekpetr mir21mir34amir198andmir217asdiagnosticandprognosticbiomarkersforchronicpancreatitisandpancreaticductaladenocarcinoma
AT vyzularostislav mir21mir34amir198andmir217asdiagnosticandprognosticbiomarkersforchronicpancreatitisandpancreaticductaladenocarcinoma
AT slabyondrej mir21mir34amir198andmir217asdiagnosticandprognosticbiomarkersforchronicpancreatitisandpancreaticductaladenocarcinoma